We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nu Skin (NUS) Down 28% in 3 Months: What's the Next Best Move?
Read MoreHide Full Article
Nu Skin Enterprises, Inc. (NUS - Free Report) has not been in its best shape lately, with its shares down 27.7% in the past three months compared with the industry’s 21.3% decline. Additionally, this beauty and wellness product company has trailed the broader Zacks Consumer Staples sector and the S&P 500’s respective growth of 1.2% and 4.2%.
Despite being a prominent player in the beauty and wellness industry, Nu Skin has struggled to navigate a series of macroeconomic headwinds that have dampened consumer spending, particularly on premium products. Additionally, the company has been severely impacted by stronger-than-expected foreign currency fluctuations and ongoing pressures within the direct selling industry, contributing to a disappointing second-quarter 2024 performance.
Considering the company’s first-half 2024 performance and rising foreign exchange headwinds, management tightened the annual guidance range for 2024 in its second-quarter earnings release.
Image Source: Zacks Investment Research
Macroeconomic Hurdles Persist
Nu Skin has been encountering persistent macroeconomic obstacles, which continued in the second quarter of 2024. The company’s performance was hurt by continuous macroeconomic headwinds across most regions, which weighed on consumer spending and customer acquisition, especially for premium products. Additionally, NUS grappled with pressures in the direct selling industry.
These headwinds, along with foreign adverse currency fluctuations, hurt Nu Skin’s quarterly revenues, which tumbled 12.2% year over year to $439.1 million in the second quarter. On a constant-currency basis, revenues fell 8%. Sales leaders were down 16% year over year to 38,592. Nu Skin’s customer base dropped 14% to 893,514. The company’s paid affiliates were down 17% to 155,486. On an adjusted basis, paid affiliates tumbled 9%.
Volatile Currency Movements
Nu Skin’s strong international presence exposes it to the risk of volatile currency movements. Any adverse currency fluctuation is likely to weigh on the company’s operating performance. Nu Skin’s second-quarter 2024 revenues witnessed strong currency headwinds. Revenues included a negative impact of 4.2% from foreign currency fluctuations. The company envisions unfavorable foreign currency impacts of around 4-3% on third-quarter and 2024 revenues.
Bumpy Road Ahead
The operating environment for Nu Skin's core business remains challenging, primarily due to macroeconomic factors and pressures within the direct selling industry. Nu Skin now anticipates revenues in the band of $1.73-$1.81 billion for 2024, which suggests a 12-8% decline from the year-ago period’s reported figure. Earlier, the metric was expected in the range of $1.73-$1.87 billion. Management envisions an adjusted earnings per share (EPS) of 75-95 cents. The projection suggests a decline from adjusted earnings of $1.85 recorded in 2023. Management had earlier envisioned an adjusted EPS of 95 cents to $1.35 for 2024.
For the third quarter of 2024, the company expects revenues between $430 million and $465 million, which suggests a decline of 14% to 7% from the year-ago quarter’s reported level. NUS expects adjusted earnings in the band of 15-25 cents a share in the third quarter compared with 56 cents recorded in the same period last year.
Estimates Lose Sheen
The Zacks Consensus Estimate for 2024 earnings per share has declined from $1.10 to 78 cents over the past 30 days. The consensus estimate for the third-quarter EPS has tumbled from 48 to 20 cents in the same time frame. This downward adjustment reflects a negative sentiment among analysts and suggests potential challenges in achieving projected profitability.
Image Source: Zacks Investment Research
Wrapping Up
Nu Skin is navigating through a turbulent period, with its stock performance reflecting the ongoing macroeconomic and industry-specific challenges. While the company is actively pursuing strategic initiatives to reinvigorate its market presence and drive growth through new product launches and the strength of its Rhyz business, these efforts may take time to bear fruit. In the near term, the combination of persistent headwinds and tighter guidance suggests that Nu Skin faces a difficult road ahead.
Investors should remain cautious, keeping a close eye on how the company manages these challenges and whether its strategic initiatives can offset the current pressures. Nu Skin presently carries a Zacks Rank #5 (Strong Sell).
Better-Ranked Staple Bets
The Chef’s Warehouse (CHEF - Free Report) , which distributes specialty food and center-of-the-plate products, has a trailing four-quarter earnings surprise of 33.7%, on average. CHEF currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for The Chef’s Warehouse’s current financial-year sales and earnings calls for growth of 9.7% and 12.6%, respectively, from the prior-year reported level.
Vital Farms (VITL - Free Report) offers a range of produced pasture-raised foods. It currently carries a Zacks Rank #2 (Buy). VITL has a trailing four-quarter earnings surprise of 82.5%, on average.
The Zacks Consensus Estimate for Vital Farms’ current financial-year earnings indicates growth of 72.9% from the year-ago reported numbers.
Nomad Foods (NOMD - Free Report) , carrying a Zacks Rank #2, manufactures and distributes frozen foods. NOMD has a trailing four-quarter earnings surprise of 3.1%, on average.
The Zacks Consensus Estimate for Nomad Foods’ current financial-year sales and earnings implies growth of 4.3% and 11.5%, respectively, from the prior-year reported level.
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Nu Skin (NUS) Down 28% in 3 Months: What's the Next Best Move?
Nu Skin Enterprises, Inc. (NUS - Free Report) has not been in its best shape lately, with its shares down 27.7% in the past three months compared with the industry’s 21.3% decline. Additionally, this beauty and wellness product company has trailed the broader Zacks Consumer Staples sector and the S&P 500’s respective growth of 1.2% and 4.2%.
Despite being a prominent player in the beauty and wellness industry, Nu Skin has struggled to navigate a series of macroeconomic headwinds that have dampened consumer spending, particularly on premium products. Additionally, the company has been severely impacted by stronger-than-expected foreign currency fluctuations and ongoing pressures within the direct selling industry, contributing to a disappointing second-quarter 2024 performance.
Considering the company’s first-half 2024 performance and rising foreign exchange headwinds, management tightened the annual guidance range for 2024 in its second-quarter earnings release.
Image Source: Zacks Investment Research
Macroeconomic Hurdles Persist
Nu Skin has been encountering persistent macroeconomic obstacles, which continued in the second quarter of 2024. The company’s performance was hurt by continuous macroeconomic headwinds across most regions, which weighed on consumer spending and customer acquisition, especially for premium products. Additionally, NUS grappled with pressures in the direct selling industry.
These headwinds, along with foreign adverse currency fluctuations, hurt Nu Skin’s quarterly revenues, which tumbled 12.2% year over year to $439.1 million in the second quarter. On a constant-currency basis, revenues fell 8%. Sales leaders were down 16% year over year to 38,592. Nu Skin’s customer base dropped 14% to 893,514. The company’s paid affiliates were down 17% to 155,486. On an adjusted basis, paid affiliates tumbled 9%.
Volatile Currency Movements
Nu Skin’s strong international presence exposes it to the risk of volatile currency movements. Any adverse currency fluctuation is likely to weigh on the company’s operating performance. Nu Skin’s second-quarter 2024 revenues witnessed strong currency headwinds. Revenues included a negative impact of 4.2% from foreign currency fluctuations. The company envisions unfavorable foreign currency impacts of around 4-3% on third-quarter and 2024 revenues.
Bumpy Road Ahead
The operating environment for Nu Skin's core business remains challenging, primarily due to macroeconomic factors and pressures within the direct selling industry. Nu Skin now anticipates revenues in the band of $1.73-$1.81 billion for 2024, which suggests a 12-8% decline from the year-ago period’s reported figure. Earlier, the metric was expected in the range of $1.73-$1.87 billion. Management envisions an adjusted earnings per share (EPS) of 75-95 cents. The projection suggests a decline from adjusted earnings of $1.85 recorded in 2023. Management had earlier envisioned an adjusted EPS of 95 cents to $1.35 for 2024.
For the third quarter of 2024, the company expects revenues between $430 million and $465 million, which suggests a decline of 14% to 7% from the year-ago quarter’s reported level. NUS expects adjusted earnings in the band of 15-25 cents a share in the third quarter compared with 56 cents recorded in the same period last year.
Estimates Lose Sheen
The Zacks Consensus Estimate for 2024 earnings per share has declined from $1.10 to 78 cents over the past 30 days. The consensus estimate for the third-quarter EPS has tumbled from 48 to 20 cents in the same time frame. This downward adjustment reflects a negative sentiment among analysts and suggests potential challenges in achieving projected profitability.
Image Source: Zacks Investment Research
Wrapping Up
Nu Skin is navigating through a turbulent period, with its stock performance reflecting the ongoing macroeconomic and industry-specific challenges. While the company is actively pursuing strategic initiatives to reinvigorate its market presence and drive growth through new product launches and the strength of its Rhyz business, these efforts may take time to bear fruit. In the near term, the combination of persistent headwinds and tighter guidance suggests that Nu Skin faces a difficult road ahead.
Investors should remain cautious, keeping a close eye on how the company manages these challenges and whether its strategic initiatives can offset the current pressures. Nu Skin presently carries a Zacks Rank #5 (Strong Sell).
Better-Ranked Staple Bets
The Chef’s Warehouse (CHEF - Free Report) , which distributes specialty food and center-of-the-plate products, has a trailing four-quarter earnings surprise of 33.7%, on average. CHEF currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for The Chef’s Warehouse’s current financial-year sales and earnings calls for growth of 9.7% and 12.6%, respectively, from the prior-year reported level.
Vital Farms (VITL - Free Report) offers a range of produced pasture-raised foods. It currently carries a Zacks Rank #2 (Buy). VITL has a trailing four-quarter earnings surprise of 82.5%, on average.
The Zacks Consensus Estimate for Vital Farms’ current financial-year earnings indicates growth of 72.9% from the year-ago reported numbers.
Nomad Foods (NOMD - Free Report) , carrying a Zacks Rank #2, manufactures and distributes frozen foods. NOMD has a trailing four-quarter earnings surprise of 3.1%, on average.
The Zacks Consensus Estimate for Nomad Foods’ current financial-year sales and earnings implies growth of 4.3% and 11.5%, respectively, from the prior-year reported level.